TCON: מכפיל P/S TRACON

TRACON Pharmaceuticals management is finalizing asset liquidation following the suspension of core programs, which is directly impacting the share price. The market cap-to-revenue ratio demonstrates volatility, with the current level standing at 0.00. The company previously relied on low molecule testing costs and inelastic demand in oncology, while simultaneously implementing energy saving and safe chemical disposal in its laboratories.

Low fundamental multiples in this case do not signal undervaluation, but rather reflect a critical breakdown of the business model. Analyzing the enterprise value-to-revenue ratio, an investor sees the market valuation of every dollar of sales, which for TRACON Pharmaceuticals (TCON) is plummeting amid failed clinical trials and a genuine threat of total liquidation.